Website intended for a NZ health professional readership
Pharmacist prescriber Linda Bryant looks at two answers to the same question about quetiapine – one from a clinical pharmacist and the other from ChatGPT
1. Ministry of Health. Cardiovascular Disease Risk Assessment and Management for Primary Care. Wellington, NZ: Ministry of Health; 2018.
2. Wu H, Siafis S, Hamza T, et al. Antipsychotic-induced weight gain: Dose-response meta-analysis of randomized controlled trials. Schizophr Bull 2022;48(3):643–54.
3. Stogios N, Smith E, Bowden S, et al. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Neuropsychopharmacology 2022;47(3):664–72.
4. Williams SG, Alinejad NA, Williams JA, Cruess DF. Statistically significant increase in weight caused by low-dose quetiapine. Pharmacotherapy 2010;30(10):1011–15.
5. Ventriglio A, Baldessarini RJ, Vitrani G, et al. Metabolic syndrome in psychotic disorder patients treated with oral and long-acting injected antipsychotics. Front Psychiatry 2019;9:744.
6. Hardy M, Harvey H. Artificial intelligence in diagnostic imaging: impact on the radiography profession. Br J Radiol 2020;93(1108):20190840.
7. Moingeon P. Artificial intelligence-driven drug development against autoimmune diseases. Trends Pharmacol Sci 2023;44(7):411–24.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
